• Lawyers
  • Practices
  • COVID-19 Resources
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Biography
  • Education
  • Recent Publications
Profile Picture

Ryan A. Murr

Ryan
Murr

Partner

CONTACT INFO

rmurr@gibsondunn.com

TEL:+1 415.393.8373

FAX:+1 415.374.8430

San Francisco

555 Mission Street, Suite 3000, San Francisco, CA 94105-0921 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

Life Sciences Capital Markets Mergers and Acquisitions Private Equity Securities Regulation and Corporate Governance

BIOGRAPHY

Ryan Murr is a partner in the San Francisco office of Gibson, Dunn & Crutcher, where he serves as a member of the firm’s Corporate Department, with a practice focused on representing leading companies and investors in the life sciences and technology space.  Mr. Murr currently serves as a Co-Chair of the firm’s Life Sciences Practice Group and previously served as a member of the firm’s Executive Committee and Management Committee.

Mr. Murr represents public and private companies and investors in the biotechnology, pharmaceutical, technology, medical device and diagnostics industries in connection with securities offerings and business combination transactions.  In addition, Mr. Murr regularly serves as principal outside counsel for publicly traded companies and private venture-backed companies, advising management teams and boards of directors on corporate law matters, SEC reporting, corporate governance, licensing transactions, and mergers & acquisitions.

Recognized by Chambers USA in the area of Life Sciences, clients describe Mr. Murr as “creative and smart” and someone who “gets the better of the other side.”

Legal Media Group (Euromoney) has ranked Mr. Murr nationally as a “Star” in Life Sciences in the areas of Corporate, Licensing & Collaboration, Mergers & Acquisitions and Venture Capital.  Mr. Murr has twice been nominated by Legal Media Group as “Finance & Transactional Attorney of the Year.”

Mr. Murr has served as a member of the American Bar Association’s Mergers and Acquisitions Subcommittee and is active in advising various not-for-profit entities in the San Francisco Bay Area.

Capital Markets Experience

Mr. Murr regularly represents issuers in a range of capital markets transactions, including initial public offerings, private placements (ranging from early-stage investments to crossover rounds and PIPEs), follow-on equity financings and debt financings. Mr. Murr has deep experience with a range of financing transaction structures beyond traditional underwritten offerings, including at-the-market offerings, rights offerings, PIPEs, and equity lines.  Recent transactions have included initial public offerings for Shattuck Labs, Progenity, Inc. 89bio, Inc. and Odonate Therapeutics.  Over the past five years, Mr. Murr has led approximately 60 issuer-side equity offerings for life sciences companies, raising nearly $5 billion in gross proceeds during that time.

Mr. Murr also regularly represents investors in the life sciences and technology space, including private equity funds, hedge funds, and venture capital funds.  Financing transactions have included public and private offerings ranging from passive investments to bespoke control structures and spin-outs.

Representative M&A Transactions

Mr. Murr regularly advises pharmaceutical, biotechnology, technology, and medical device and diagnostic companies in connection with significant strategic transactions, including tender offers, public and private mergers, and stock and asset purchases.  Noteworthy engagements have included:

  • The representation of Gilead Sciences in the acquisition of MYR GmbH for €1.15 billion, plus contingent consideration.
  • The acquisition of Tetraphase Pharmaceuticals, Inc. for cash and a contingent value right in a topping bid made by La Jolla Pharmaceutical Company.
  • The acquisition of Zyla Life Sciences by Assertio Therapeutics in a stock-for-stock merger.
  • Sale of US WorldMeds CNS product portfolio to Supernus Pharmaceuticals for $530 million.
  • Sale of NUCYNTA product franchise to Collegium Pharmaceutical for $375 million.
  • Reverse merger transactions with concurrent PIPE financings for Novus Therapeutics (acquiring Anelixis Therapeutics), Kiq Bio (sale to Cogent Biosciences) and Viridian Therapeutics (sale to Miragen Therapeutics).
  • The successful defense of Depomed (Assertio) in the attempted hostile takeover by Horizon Pharma Plc, initially valued by Horizon at $3 billion.
  • The representation of Ultragenyx Pharmaceutical in its sale of two a Rare Pediatric Disease Priority Review Vouchers awarded by the U.S. Food and Drug Administration.
  • The representation of Assertio Therapeutics in a licensing and collaboration transaction involving the commercialization of certain specialty pharmaceutical products.
  • The representation of Rocket Pharmaceuticals in its $315 million merger with Inotek Pharmaceuticals.
  • The representation of Silicon Graphics International (SGI) in the sale to Hewlett Packard Enterprise.
  • The representation of Lazard as financial advisor in Alexion’s acquisition of Synageva for $8.3 billion.
  • The representation of Lazard as financial advisor in a $500 million cross-border merger-of-equals.
  • The acquisition and in-license from Novartis and Roche of assets and intellectual property rights to their RNAi platforms.
  • The sale of global rights to an approved antiviral drug approved for use in the hospital setting.
  • The acquisition and disposition of broad technology platforms, as well as rights to individual products and drugs in the United States and globally, including a transaction involving the establishment of a strategic collaboration and license agreement in the cardiovascular space, coupled with an equity investment, valued at more than $670 million.

Royalty Monetization Transactions

Mr. Murr also has significant experience in royalty monetization transactions, representing both purchasers and sellers of royalty entitlements, including synthetic royalty financing transactions.  These engagements have included representing academic institutions, corporate licensors, royalty investment funds and hedge funds in a range of royalty financing transactions and structures.

Notable monetization transactions have included the following:

  • The representation of UCLA in the sale of two royalty streams (Xtandi and Erleada), including one sale with a transaction valued at $1.145 billion, which was the largest monetization transaction at that time by an academic institution.
  • Synthetic royalty financing for BioCryst Pharmaceuticals, Inc., selling a royalty “strip” to Royalty Pharma for $125 million.
  • Milestone-based financing facility of $100 million for clinical-stage dermatology assets.
  • Synthetic royalty financing selling a $125 million interest in Giapreza, a marketed drug to increase blood pressure for patients with septic or other distributive shock.
  • Sale of European royalty rights to Crysvita for $320 million.
  • Acquisition of royalty entitlements to Edurant and Complera, two approved products for the treatment of HIV.

Recognition and Rankings

  • Chambers USA:  Life Sciences: Corporate/Commercial – California. Client feedback includes the following commentary: “creative and smart” and someone who “gets the better of the other side” (2019).  Mr. Murr is “extremely smart and experienced” and “his expertise and knowhow within life sciences has proven extremely valuable” (2020).
  • IFLR1000: Rated “Highly Regarded” in California for Capital Markets (the only practitioner in California receiving this ranking in Life Sciences).
  • LMG Life Sciences: Rated a “Star” in the areas of Corporate, Licensing & Collaboration, Mergers & Acquisitions, Venture Capital. Twice nominated as “Finance & Transactional Attorney of the Year.”

Select Presentations and Press

  • Moderator, “SEC Up-close”, Gibson Dunn Webinar (San Francisco)
  • Speaker, “Raising Capital in the Current Environment: ATM Programs and Rights Offerings”, Gibson Dunn Webinar (San Francisco)
  • Speaker, “How Boards Should Handle Securities Compliance, Corporate Governance and M&A”, Directors Roundtable (Palo Alto)
  • “Big Suits – Depomed v. Horizon Pharma”, American Lawyer
  • Speaker, “Facilitating Successful Merger & Acquisition Transactions,” ABA / AICPA Summit on Emerging Corporate Governance Trends (Chicago)
  • Moderator, “Effective Communication Between Attorneys, Accountants and the Audit Committee,” ABA / AICPA Summit on Emerging Corporate Governance Trends (Chicago)
  • Panelist, Berkeley Postdoc Entrepreneur Program (BPEP) Workshop:How to finance your idea (Berkeley)
  • Speaker, The Impact of Market Dynamics on Health Care and Pharmaceutical Acquisitions
  • Panel Moderator, BIO General Counsels Committee Meeting:  Evolving Issues in BioPharma Collaborations (New York)
  • Speaker, Deloitte Tohmatsu Global M&A Seminar:  U.S. Healthcare M&A Overview (Tokyo, Japan)
  • Speaker, Korean Pharmaceutical Manufacturers Association:  U.S. Healthcare M&A Overview (Seoul, Korea)
  • Panel Moderator, BioPharm Partnering Conference:  Structured Transactions in M&A (San Francisco)
  • Contingent Value Rights: A Middle Ground in M&A Boom, Daily Journal

EDUCATION

University of San Diego - 1998 Juris Doctor

University of San Diego - 1998 Master of Arts

University of Oregon - 1993 Bachelor of Arts

ADMISSIONS

California Bar

RECENT PUBLICATIONS

Firm News - October 8, 2020 | LMG Life Sciences Names 13 Partners as Stars
Publications - September 29, 2020 | Webcast: Raising Capital in the Current Environment V: ATM Programs and Rights Offerings
Client Alert - March 31, 2020 | COVID-19 And Life Sciences Companies – 10 Actions To Consider
Firm News - October 7, 2019 | LMG Life Sciences Names 12 Partners as Stars
Firm News - October 31, 2018 | LMG Life Sciences Recognizes Gibson Dunn in Six Practices and Names 11 Lawyers Stars
Client Alert - November 15, 2016 | The Trump Presidency: Selected Initial Observations and Considerations
Client Alert - September 11, 2014 | Contingent Value Rights: A Middle Ground in M&A Boom
Client Alert - September 9, 2014 | Long-Term Outlook for M&A is More Modest
  • Sitemap
  • Client Extranet
  • Legal Notices
  • Privacy Policy
  • Cookie Notice
  • Contact Us
©Gibson, Dunn & Crutcher LLP 2021. All rights reserved.
Top
This website uses cookies to provide analytics on user traffic. By continuing to browse our website, you consent to our use of cookies as set forth in our Cookie Policy. However you may visit Cookie Settings to customize your consent.
Cookie SettingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Analytics

Cookies that tie into analytics systems, such as Google Analytics, YouTube and Vimeo analytics for embedded video, etc. The following are the cookies installed by the service: _ga, _gid, collect, vuid

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The following cookie is installed by the Google Analytics service: _gat

Save & Accept